Follow us:

For Investors

 

Highlights:

  • InspireMD addresses a growing, $1.8B market
  • Target market has limited competition
  • Aging population and desire for less invasive therapies create favorable growth demographics

 

InspireMD to Host Conference Call and Webinar and to Discuss Recently Released Results of CGuard™ CARENET Trial on Wednesday, September 24 at 8:30 AM ET

A live webcast will be available. Please click on the following link:

 

http://public.viavid.com/player/index.php?id=111009

U.S. Dial-in: (877) 407-0789

International Dial-in: (201) 689-8562

 

InspireMD to Present at the Aegis Healthcare and Technology Conference on Friday, September 12, 2014 at 8:30 a.m. PT.

 

A live webcast will be available. Please click on the following link:

 

 

Summary:

InspireMD Ltd. is a high growth medical device company focusing on the development and commercialization of its proprietary stent platform technology: MGuard™.

 

InspireMD has created a unique, patent-pending mesh net technology that wraps a stent, providing embolic protection (preventing Major Adverse Cardiac Events (MACE) by filtering debris) and reducing vessel injury by spreading strut pressure. MGuard™ is delivered with no change to the current procedure and is well-accepted by physicians. MGuard™ has been implanted in thousands of patients, and in clinical trials it has shown a more than 50% reduction in MACE compared with traditional bare metal stents.

ASTUDIO | Design & Development